Specific NEMO mutations impair CD40-mediated c-Rel activation and B cell terminal differentiation
Identifieur interne : 003E03 ( Pmc/Checkpoint ); précédent : 003E02; suivant : 003E04Specific NEMO mutations impair CD40-mediated c-Rel activation and B cell terminal differentiation
Auteurs : Ashish Jain [États-Unis] ; Chi A. Ma [États-Unis] ; Eduardo Lopez-Granados [États-Unis] ; Gary Means [États-Unis] ; William Brady [États-Unis] ; Jordan S. Orange [États-Unis] ; Shuying Liu [États-Unis] ; Steven Holland [États-Unis] ; Jonathan M. J. Derry [États-Unis]Source :
- Journal of Clinical Investigation [ 0021-9738 ] ; 2004.
Abstract
Hypomorphic mutations in the zinc finger domain of NF-κB essential modulator (NEMO) cause X-linked hyper-IgM syndrome with ectodermal dysplasia (XHM-ED). Here we report that patient B cells are characterized by an absence of Ig somatic hypermutation (SHM) and defective class switch recombination (CSR) despite normal induction of activation-induced cytidine deaminase (AID) and Iε-Cε transcripts. This indicates that AID expression alone is insufficient to support neutralizing antibody responses. Furthermore, we show that patient B cells stimulated with CD40 ligand are impaired in both p65 and c-Rel activation, and whereas addition of IL-4 can enhance p65 activity, c-Rel activity remains deficient. This suggests that these NF-κB components have different activation requirements and that IL-4 can augment some but not all NEMO-dependent NF-κB signaling. Finally, using microarray analysis of patient B cells we identified downstream effects of impaired NF-κB activation and candidate factors that may be necessary for CSR and SHM in B cells.
Url:
DOI: 10.1172/JCI200421345
PubMed: 15578091
PubMed Central: 529497
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:529497Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Specific NEMO mutations impair CD40-mediated c-Rel activation and B cell terminal differentiation</title><author><name sortKey="Jain, Ashish" sort="Jain, Ashish" uniqKey="Jain A" first="Ashish" last="Jain">Ashish Jain</name><affiliation wicri:level="2"><nlm:aff id="N0x95f6eb8.0xa12d098">Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Ma, Chi A" sort="Ma, Chi A" uniqKey="Ma C" first="Chi A." last="Ma">Chi A. Ma</name><affiliation wicri:level="2"><nlm:aff id="N0x95f6eb8.0xa12d098">Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Lopez Granados, Eduardo" sort="Lopez Granados, Eduardo" uniqKey="Lopez Granados E" first="Eduardo" last="Lopez-Granados">Eduardo Lopez-Granados</name><affiliation wicri:level="2"><nlm:aff id="N0x95f6eb8.0xa12d098">Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Means, Gary" sort="Means, Gary" uniqKey="Means G" first="Gary" last="Means">Gary Means</name><affiliation wicri:level="2"><nlm:aff id="N0x95f6eb8.0xa12d098">Amgen Inc., Seattle, Washington, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Amgen Inc., Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Brady, William" sort="Brady, William" uniqKey="Brady W" first="William" last="Brady">William Brady</name><affiliation wicri:level="2"><nlm:aff id="N0x95f6eb8.0xa12d098">Amgen Inc., Seattle, Washington, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Amgen Inc., Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Orange, Jordan S" sort="Orange, Jordan S" uniqKey="Orange J" first="Jordan S." last="Orange">Jordan S. Orange</name><affiliation wicri:level="2"><nlm:aff id="N0x95f6eb8.0xa12d098">Division of Immunology, Children’s Hospital Boston, Boston, Massachusetts, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Division of Immunology, Children’s Hospital Boston, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Liu, Shuying" sort="Liu, Shuying" uniqKey="Liu S" first="Shuying" last="Liu">Shuying Liu</name><affiliation wicri:level="2"><nlm:aff id="N0x95f6eb8.0xa12d098">Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Holland, Steven" sort="Holland, Steven" uniqKey="Holland S" first="Steven" last="Holland">Steven Holland</name><affiliation wicri:level="2"><nlm:aff id="N0x95f6eb8.0xa12d098">Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Derry, Jonathan M J" sort="Derry, Jonathan M J" uniqKey="Derry J" first="Jonathan M. J." last="Derry">Jonathan M. J. Derry</name><affiliation wicri:level="2"><nlm:aff id="N0x95f6eb8.0xa12d098">Amgen Inc., Seattle, Washington, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Amgen Inc., Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">15578091</idno><idno type="pmc">529497</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC529497</idno><idno type="RBID">PMC:529497</idno><idno type="doi">10.1172/JCI200421345</idno><date when="2004">2004</date><idno type="wicri:Area/Pmc/Corpus">000B62</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000B62</idno><idno type="wicri:Area/Pmc/Curation">000B61</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000B61</idno><idno type="wicri:Area/Pmc/Checkpoint">003E03</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003E03</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Specific NEMO mutations impair CD40-mediated c-Rel activation and B cell terminal differentiation</title><author><name sortKey="Jain, Ashish" sort="Jain, Ashish" uniqKey="Jain A" first="Ashish" last="Jain">Ashish Jain</name><affiliation wicri:level="2"><nlm:aff id="N0x95f6eb8.0xa12d098">Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Ma, Chi A" sort="Ma, Chi A" uniqKey="Ma C" first="Chi A." last="Ma">Chi A. Ma</name><affiliation wicri:level="2"><nlm:aff id="N0x95f6eb8.0xa12d098">Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Lopez Granados, Eduardo" sort="Lopez Granados, Eduardo" uniqKey="Lopez Granados E" first="Eduardo" last="Lopez-Granados">Eduardo Lopez-Granados</name><affiliation wicri:level="2"><nlm:aff id="N0x95f6eb8.0xa12d098">Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Means, Gary" sort="Means, Gary" uniqKey="Means G" first="Gary" last="Means">Gary Means</name><affiliation wicri:level="2"><nlm:aff id="N0x95f6eb8.0xa12d098">Amgen Inc., Seattle, Washington, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Amgen Inc., Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Brady, William" sort="Brady, William" uniqKey="Brady W" first="William" last="Brady">William Brady</name><affiliation wicri:level="2"><nlm:aff id="N0x95f6eb8.0xa12d098">Amgen Inc., Seattle, Washington, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Amgen Inc., Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Orange, Jordan S" sort="Orange, Jordan S" uniqKey="Orange J" first="Jordan S." last="Orange">Jordan S. Orange</name><affiliation wicri:level="2"><nlm:aff id="N0x95f6eb8.0xa12d098">Division of Immunology, Children’s Hospital Boston, Boston, Massachusetts, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Division of Immunology, Children’s Hospital Boston, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Liu, Shuying" sort="Liu, Shuying" uniqKey="Liu S" first="Shuying" last="Liu">Shuying Liu</name><affiliation wicri:level="2"><nlm:aff id="N0x95f6eb8.0xa12d098">Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Holland, Steven" sort="Holland, Steven" uniqKey="Holland S" first="Steven" last="Holland">Steven Holland</name><affiliation wicri:level="2"><nlm:aff id="N0x95f6eb8.0xa12d098">Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Derry, Jonathan M J" sort="Derry, Jonathan M J" uniqKey="Derry J" first="Jonathan M. J." last="Derry">Jonathan M. J. Derry</name><affiliation wicri:level="2"><nlm:aff id="N0x95f6eb8.0xa12d098">Amgen Inc., Seattle, Washington, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Amgen Inc., Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author></analytic><series><title level="j">Journal of Clinical Investigation</title><idno type="ISSN">0021-9738</idno><imprint><date when="2004">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Hypomorphic mutations in the zinc finger domain of NF-κB essential modulator (NEMO) cause X-linked hyper-IgM syndrome with ectodermal dysplasia (XHM-ED). Here we report that patient B cells are characterized by an absence of Ig somatic hypermutation (SHM) and defective class switch recombination (CSR) despite normal induction of activation-induced cytidine deaminase (AID) and Iε-Cε transcripts. This indicates that AID expression alone is insufficient to support neutralizing antibody responses. Furthermore, we show that patient B cells stimulated with CD40 ligand are impaired in both p65 and c-Rel activation, and whereas addition of IL-4 can enhance p65 activity, c-Rel activity remains deficient. This suggests that these NF-κB components have different activation requirements and that IL-4 can augment some but not all NEMO-dependent NF-κB signaling. Finally, using microarray analysis of patient B cells we identified downstream effects of impaired NF-κB activation and candidate factors that may be necessary for CSR and SHM in B cells.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Invest</journal-id><journal-id journal-id-type="publisher-id">J CLIN INVEST</journal-id><journal-title>Journal of Clinical Investigation</journal-title><issn pub-type="ppub">0021-9738</issn><publisher><publisher-name>American Society for Clinical Investigation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15578091</article-id><article-id pub-id-type="pmc">529497</article-id><article-id pub-id-type="publisher-id">21345</article-id><article-id pub-id-type="doi">10.1172/JCI200421345</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Specific NEMO mutations impair CD40-mediated c-Rel activation and B cell terminal differentiation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jain</surname><given-names>Ashish</given-names></name><xref ref-type="aff" rid="N0x95f6eb8.0xa12d098">1</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Chi A.</given-names></name><xref ref-type="aff" rid="N0x95f6eb8.0xa12d098">1</xref></contrib><contrib contrib-type="author"><name><surname>Lopez-Granados</surname><given-names>Eduardo</given-names></name><xref ref-type="aff" rid="N0x95f6eb8.0xa12d098">1</xref></contrib><contrib contrib-type="author"><name><surname>Means</surname><given-names>Gary</given-names></name><xref ref-type="aff" rid="N0x95f6eb8.0xa12d098">2</xref></contrib><contrib contrib-type="author"><name><surname>Brady</surname><given-names>William</given-names></name><xref ref-type="aff" rid="N0x95f6eb8.0xa12d098">2</xref></contrib><contrib contrib-type="author"><name><surname>Orange</surname><given-names>Jordan S.</given-names></name><xref ref-type="aff" rid="N0x95f6eb8.0xa12d098">3</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Shuying</given-names></name><xref ref-type="aff" rid="N0x95f6eb8.0xa12d098">1</xref></contrib><contrib contrib-type="author"><name><surname>Holland</surname><given-names>Steven</given-names></name><xref ref-type="aff" rid="N0x95f6eb8.0xa12d098">1</xref></contrib><contrib contrib-type="author"><name><surname>Derry</surname><given-names>Jonathan M.J.</given-names></name><xref ref-type="aff" rid="N0x95f6eb8.0xa12d098">2</xref></contrib></contrib-group><aff id="N0x95f6eb8.0xa12d098"><label>1</label>Laboratory of Host Defense, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.<label>2</label>Amgen Inc., Seattle, Washington, USA.<label>3</label>Division of Immunology, Children’s Hospital Boston, Boston, Massachusetts, USA.</aff><author-notes><fn><p>Address correspondence to: Ashish Jain, Laboratory of Host Defense, NIAID, NIH, Bethesda, Maryland 20892, USA. Phone: (301) 594-5691; Fax: (301) 480-1753; E-mail: ajain@niaid.nih.gov. Or to: Jonathan M.J. Derry, Amgen Inc., 1201 Amgen Court West, Seattle, Washington 98119, USA. E-mail: <email>derryjmj@amgen.com</email>.</p></fn></author-notes><pub-date pub-type="ppub"><day>1</day><month>12</month><year>2004</year></pub-date><volume>114</volume><issue>11</issue><fpage>1593</fpage><lpage>1602</lpage><copyright-statement>Copyright © 2004, American Society for Clinical Investigation</copyright-statement><copyright-year>2004</copyright-year><abstract><p>Hypomorphic mutations in the zinc finger domain of NF-κB essential modulator (NEMO) cause X-linked hyper-IgM syndrome with ectodermal dysplasia (XHM-ED). Here we report that patient B cells are characterized by an absence of Ig somatic hypermutation (SHM) and defective class switch recombination (CSR) despite normal induction of activation-induced cytidine deaminase (AID) and Iε-Cε transcripts. This indicates that AID expression alone is insufficient to support neutralizing antibody responses. Furthermore, we show that patient B cells stimulated with CD40 ligand are impaired in both p65 and c-Rel activation, and whereas addition of IL-4 can enhance p65 activity, c-Rel activity remains deficient. This suggests that these NF-κB components have different activation requirements and that IL-4 can augment some but not all NEMO-dependent NF-κB signaling. Finally, using microarray analysis of patient B cells we identified downstream effects of impaired NF-κB activation and candidate factors that may be necessary for CSR and SHM in B cells.</p></abstract></article-meta></front></pmc><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li><li>Massachusetts</li><li>Washington (État)</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Jain, Ashish" sort="Jain, Ashish" uniqKey="Jain A" first="Ashish" last="Jain">Ashish Jain</name></region><name sortKey="Brady, William" sort="Brady, William" uniqKey="Brady W" first="William" last="Brady">William Brady</name><name sortKey="Derry, Jonathan M J" sort="Derry, Jonathan M J" uniqKey="Derry J" first="Jonathan M. J." last="Derry">Jonathan M. J. Derry</name><name sortKey="Holland, Steven" sort="Holland, Steven" uniqKey="Holland S" first="Steven" last="Holland">Steven Holland</name><name sortKey="Liu, Shuying" sort="Liu, Shuying" uniqKey="Liu S" first="Shuying" last="Liu">Shuying Liu</name><name sortKey="Lopez Granados, Eduardo" sort="Lopez Granados, Eduardo" uniqKey="Lopez Granados E" first="Eduardo" last="Lopez-Granados">Eduardo Lopez-Granados</name><name sortKey="Ma, Chi A" sort="Ma, Chi A" uniqKey="Ma C" first="Chi A." last="Ma">Chi A. Ma</name><name sortKey="Means, Gary" sort="Means, Gary" uniqKey="Means G" first="Gary" last="Means">Gary Means</name><name sortKey="Orange, Jordan S" sort="Orange, Jordan S" uniqKey="Orange J" first="Jordan S." last="Orange">Jordan S. Orange</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E03 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 003E03 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:529497
|texte= Specific NEMO mutations impair CD40-mediated c-Rel activation and B cell terminal differentiation
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:15578091" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |